Results 111 to 120 of about 6,410,935 (343)

Vertical Product Differentiation, Entry-Deterrence Strategies, and Entry Qualities [PDF]

We analyze the potential entry of a new product into a vertically differentiated market. Here the entry-deterrence strategies of the incumbent firm rely on ﾓlimit qualities.ﾔ The model assumes quality-dependent marginal production costs and considers
Moschini, GianCarlo, Noh, Yong-Hwan
core  

Investigating transcription factor dynamics in health and disease using FRAP

FEBS Letters, EarlyView.
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj, Carolina Vazquez Garzon, Jose Joaquin Velasco, Janine N. Post   +3 more
wiley   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Natural products as a source of Coronavirus entry inhibitors

Frontiers in Cellular and Infection Microbiology
The COVID-19 pandemic has had a significant and lasting impact on the world. Four years on, despite the existence of effective vaccines, the continuous emergence of new SARS-CoV-2 variants remains a challenge for long-term immunity.
Dávid Szabó, Dávid Szabó, Andrew Crowe, Andrew Crowe, Cyril Mamotte, Cyril Mamotte, Padraig Strappe, Padraig Strappe   +7 more
doaj   +1 more source

Characterizing the Anti-HIV Activity of Papuamide A

Marine Drugs, 2008
Papuamide A is representative of a class of marine derived cyclic depsipeptides, reported to have cytoprotective activity against HIV-1 in vitro. We show here that papuamide A acts as an entry inhibitor, preventing human immunodeficiency virus infection ...
Louis R. Barrows, Vicente Planelles, Cynthia D. Andjelic   +2 more
doaj   +1 more source

Gumming up the works: DNA polymers as HCV entry inhibitors

, 2009
Gumming up the works: DNA polymers as HCV entry ...
B Lindenbach (13713817), Natalie Counihan (13065165)   +1 more
core  

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

SELEX based aptamers with diagnostic and entry inhibitor therapeutic potential for SARS-CoV-2 [PDF]

Sci Rep, 2023
Halder S, Thakur A, Keshry SS, Acevedo O, Swain RK, Mondal A, Chattopadhyay S, Jayaprakash V, Dev A, Jana P, Karothia D, Jana ID.   +11 more
europepmc   +2 more sources

Development of Peptide Entry Inhibitors Targeting the Endosomal Receptor NPC1 Binding Site of Orthoebolavirus

Pathogens
Orthoebolavirus causes severe Ebola virus disease (EVD) and deadly outbreaks in humans. This infection occurs through macropinocytosis and trafficking to late endosomes or lysosomes that utilize the receptor Niemann–Pick C1 (NPC1) to enter the cell ...
Leah Liu Wang, Kendra Alfson, J. J. Patten, Marc E. Mattix, Yenny Goez-Gazi, Sean N. Avedissian, Robert A. Davey, Ricardo Carrion, Shi-Hua Xiang   +8 more
doaj   +1 more source

Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor

Molecules, 2018
Human immunodeficiency virus type 1 (HIV-1) is responsible for the majority of HIV infections worldwide, and we still lack a cure for this infection. Blocking the interaction of HIV-1 and its primary receptor CD4 is one strategy for identifying new anti ...
Chaozai Zhang, Huijun Zhang, Lina S. Huang, Siyu Zhu, Yan Xu, Xing-Quan Zhang, Robert T. Schooley, Xiaohong Yang, Ziwei Huang, Jing An   +9 more
doaj   +1 more source